IDEXX Laboratories (IDXX) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IDEXX Laboratories (IDXX) has outperformed Intellia Therapeutics (NTLA) over the past year, losing 18.5% versus a loss of 48.5%. Over five years, IDXX leads with a -19.2% price change compared with -90.3% for NTLA. IDEXX Laboratories is the larger company by market cap ($40.43 billion vs $1.77 billion), about 22.9 times the size, while Intellia Therapeutics is growing revenue faster (+16.9% vs +10.4%).
IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus -609.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | NTLA |
|---|---|---|
| Share price | $513.14 | $12.60 |
| Market cap | $40.43B | $1.77B |
| 1-day change | +1.28% | +7.60% |
| YTD return | -24.15% | +40.16% |
| 1-year return | -18.54% | -48.51% |
| 5-year return | -19.21% | -90.34% |
| P/E ratio (TTM) | 36.06 | — |
| Forward P/E | 30.66 | — |
| EPS (TTM) | $14.23 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $67.67M |
| Revenue growth (YoY) | +10.42% | +16.92% |
| Net income (latest FY) | $1.06B | $-412.69M |
| Gross margin | 61.80% | — |
| Operating margin | 31.60% | -651.67% |
| Net margin | 24.62% | -609.85% |
| 52-week high | $769.98 | $28.25 |
| 52-week low | $500.61 | $7.95 |
| Distance from 52-week high | -33.36% | -55.40% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +36.67% | +83.41% |
| Average volume | 553.95K | 4.26M |
| Shares outstanding | 78.78M | 140.13M |
| Employees | 11,000 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 22.9 times larger than Intellia Therapeutics by market value ($40.43B vs $1.77B).
- IDXX has outperformed NTLA by 30.0 percentage points over the past year.
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -609.9 cents for Intellia Therapeutics.
- Intellia Therapeutics grew revenue faster in its latest fiscal year (+16.92% vs +10.42%).
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
IDXX vs NTLA FAQ
Which is bigger, IDEXX Laboratories or Intellia Therapeutics?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.43B compared with $1.77B for Intellia Therapeutics (NTLA).
Which stock has performed better over the past year, IDXX or NTLA?
IDXX returned -18.54% over the past 12 months, compared with -48.51% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are IDEXX Laboratories and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.